Evidence map›Paper›PMID 42095411›Full record

ArticleAngewandte Chemie (International ed. in English)2026

Synthetic O-Polysaccharide Backbone Units for a Single Antigen Vaccine Against Two Major Non-Typhoidal Salmonella Serovars.

Xingling Pan, Changxin Huo, Soham Maity, Herbert Kavunja, Rachel Moszyk, Cameron Talbot, Scott M Baliban, Xuefei Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Xingling PanDepartment of Chemistry, Michigan State University, East Lansing, Michigan, USA.
Changxin HuoDepartment of Chemistry, Michigan State University, East Lansing, Michigan, USA.
Soham MaityIaso Therapeutics Inc., East Lansing, Michigan, USA.
Herbert KavunjaIaso Therapeutics Inc., East Lansing, Michigan, USA.
Rachel MoszykIaso Therapeutics Inc., East Lansing, Michigan, USA.
Cameron TalbotDepartment of Chemistry, Michigan State University, East Lansing, Michigan, USA.
Scott M BalibanCenter For Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, Maryland, USA.
Xuefei HuangDepartment of Chemistry, Michigan State University, East Lansing, Michigan, USA.ORCID 0000-0002-6468-5526

Funding

Deciphering the amine/acetylation code of PNAG through comprehensive libraries of synthetic oligosaccharides for effective anti-microbial vaccinesR01AI182419 · NIAID · MICHIGAN STATE UNIVERSITY · PI Xuefei Huang, Gerald B Pier · 2025 to 2026
$1.6M
Carbohydrate based multi-component vaccine against Bordetella pertussisR01AI190348 · NIAID · MICHIGAN STATE UNIVERSITY · PI RAJENDAR K DEORA, Xuefei Huang · 2025 to 2026
$1.5M
Synthetic glycan conjugates with bacteriophage Qbeta for broad spectrum anti-salmonella vaccinesR01AI146210 · NIAID · MICHIGAN STATE UNIVERSITY · PI HUANG, XUEFEI · 2019 to 2023
$1.5M
Systems Vaccinology Approaches to Define and Predict Immunity in Response to Nontyphoidal Salmonella Conjugate VaccinesK01AI168587 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI Scott M. Baliban · 2022 to 2026
$646k
Michigan State University and Michigan State University Research FoundationNational Institute of Allergy and Infectious Diseases K01AI168587 (SMB)National Institute of Allergy and Infectious Diseases R01AI146210National Institute of Allergy and Infectious Diseases R01AI182419National Institute of Allergy and Infectious Diseases R01AI190348 (XH)NIAID NIH HHS K01 AI168587NIAID NIH HHS R01 AI146210NIAID NIH HHS R01 AI182419NIAID NIH HHS R01 AI190348
6 · The paper itself

Abstract

Salmonella infections can cause life-threatening systemic diseases in many regions of the world. With the prevalence of antimicrobial-resistant Salmonella, vaccines are urgently needed to prevent and reduce infections. There are no vaccines available against any non-typhoidal Salmonella (NTS) serovars, including two of the most common ones, that are, Salmonella Typhimurium and Salmonella Enteritidis. While traditional Salmonella vaccine approaches require a construct against each serotype, a new strategy has been developed in this work targeting the shared O-polysaccharide backbone as a potential common vaccine antigen. Tri-, hexa-, and nona-saccharides corresponding to one to three repeating units of the O-polysaccharide backbone were synthesized stereoselectively via a modular approach. These oligosaccharides were conjugated to the bacteriophage Qβ carrier, which elicited strong IgG responses against the synthetic carbohydrate antigens upon immunization of both mice and rabbits. The trisaccharide antigen was sufficient to induce protective antibodies. The post-immune sera from Qβ-trisaccharide immunized rabbits recognized the native O-polysaccharides from both S. Typhimurium and S. Enteritidis, and significantly protected mice against lethal challenges by these Salmonella serotypes. The ability of a single glycan antigen to protect against infections by two different NTS serovars is a significant step forward for broad-spectrum anti-Salmonella vaccine design.

Indexed as

O AntigensSalmonella enteritidisSalmonella InfectionsSalmonella typhimuriumSalmonella VaccinesAnimalsMiceRabbitsO AntigensSalmonella Vaccinesbroad‐spectrum vaccinescarbohydrate synthesiso‐polysaccharideSalmonella EnteritidisSalmonella Typhimurium

Identifiers

PMID42095411
PMCPMC13285466

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.